Goal: Discuss how the October 2006 erythropoietin claims monitoring policy differs from the previous policy, and the implications for nursing practice.
List three ways in which the new reimbursement policy differs from the previous policy.
Discuss the rationale for not requiring fiscal intermediaries to monitor Epoetin claims until Hb levels reach 13.0 g/dL.
Describe when Epoetin doses should be modified in response to increasing Hb levels.
Note: This article is supported by an unrestricted educational grant from Amgen The manuscript has undergone peer review. The information does not necessarily reflect the opinions of ANNA or the sponsor.